KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Asset Writedowns and Impairment (2016 - 2025)

Pfizer (PFE) has disclosed Asset Writedowns and Impairment for 17 consecutive years, with $4.4 billion as the latest value for Q4 2025.

  • On a quarterly basis, Asset Writedowns and Impairment rose 1350.14% to $4.4 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $4.9 billion, a 18196.3% increase, with the full-year FY2025 number at $4.9 billion, changed N/A from a year prior.
  • Asset Writedowns and Impairment was $4.4 billion for Q4 2025 at Pfizer, up from $260.0 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $4.4 billion in Q4 2025 to a low of -$349.0 million in Q4 2024.
  • A 5-year average of $629.9 million and a median of $200.0 million in 2022 define the central range for Asset Writedowns and Impairment.
  • Peak YoY movement for Asset Writedowns and Impairment: tumbled 131.5% in 2023, then soared 1350.14% in 2025.
  • Pfizer's Asset Writedowns and Impairment stood at $31.0 million in 2021, then soared by 545.16% to $200.0 million in 2022, then surged by 1280.0% to $2.8 billion in 2023, then tumbled by 112.64% to -$349.0 million in 2024, then skyrocketed by 1350.14% to $4.4 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Asset Writedowns and Impairment are $4.4 billion (Q4 2025), $260.0 million (Q3 2025), and -$27.0 million (Q2 2025).